Derya Unutmaz, an immunologist at The Jackson Laboratory for Genomic Medicine, handed a three-year-old dataset to GPT-5 Pro and got back answers his team had been chasing since 2022. The AI model identified patterns in T cell gene expression across different age groups that had eluded traditional analysis, generating novel hypotheses that align with decades of prior research in the field.

What Unutmaz actually did

Unutmaz has spent over 30 years studying T cell biology and cancer immunotherapy. In 2025, he began using OpenAI’s GPT-5 Pro as what he describes as a research collaborator, feeding it legacy datasets on human immune cells that his lab had accumulated over years of work.

The model surfaced connections between cellular processes and T cell developmental trajectories that the team hadn’t previously identified. Analysis that would typically consume months of a researcher’s time was completed in minutes of computation.

Unutmaz received the OpenAI Pro AI Award for his pioneering contributions in this area. His work has been featured in Scientific American and on OpenAI’s own blog.

Unutmaz has been careful to stress that human oversight remains essential. The AI generates hypotheses and identifies patterns. Humans still need to design experiments, validate findings, and interpret results within the broader context of biological knowledge.

Why crypto readers should care, and why they shouldn’t

There are zero connections between Unutmaz’s research and any cryptocurrency, token, or blockchain technology. No DeSci protocol is involved. No biotech DAO funded this work. It is a purely scientific endeavor conducted at a traditional research institution using a centralized AI model built by OpenAI.

The intersection of AI and science is genuinely transformative. But transformation in immunology research does not automatically translate into value accrual for AI-themed tokens or DeSci protocols unless those projects have direct, verifiable connections to the research pipelines benefiting from these tools.

Where the real market implications land

The more honest read on market implications points toward biotech and pharmaceutical equities, not crypto. If AI can genuinely compress drug discovery and immunology research timelines from years to months, that changes the economics of therapeutic development in ways that directly benefit companies integrating these tools into their R&D pipelines.

The DeSci sector, which aims to decentralize scientific research funding and data sharing, remains in its early stages. Projects in that space would need to demonstrate that they’re actually plugged into research workflows like the one Unutmaz is running. Being thematically adjacent to AI-driven science is not the same as being structurally integrated with it.